Medtronic wins CPT approvals as TD Cowen maintains target for Medtronic stock

Published on 10/05/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen's USD 110.00 target dates to September 30, 2026. Medtronic stock costs EUR 76.90 on October 5, 2026, with a 0.44 percent change versus EUR 77.24.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und medizinischen Utensilien — Medtronic plc (ISIN IE00BTN1Y115) Flatlay kombiniert Aktienzertifikat, ISIN-Karte, Stethoskop und medizinische Utensilien, Illustration mit AI erstellt.

Medtronic plc (IE00BTN1Y115) was trading at EUR 76.90 at Lang & Schwarz on October 5, 2026 at 10:03 a.m. CEST, versus the prior close of EUR 77.24. On October 1, 2026, Medtronic announced new Category I CPT approvals for its Altaviva and Symplicity Spyral systems, while Trivano reports that the codes become effective in January 2028. Investing.com lists TD Cowen's September 30, 2026 target at USD 110.00.

CPT approvals set a 2028 timetable

The approvals cover Altaviva, an implantable tibial neuromodulation device for urge urinary incontinence, and Symplicity Spyral, a renal denervation system for uncontrolled hypertension. Medtronic said the permanent codes replace existing Category III codes and can support reimbursement discussions, although the approvals themselves do not determine coverage or clinical superiority.

That timing matters because the commercial effect is deferred: the codes become effective in January 2028, giving Medtronic a defined reimbursement milestone rather than an immediate revenue contribution. The source release also said the Symplicity Spyral clinical program includes more than 5,000 patients, a scale that supports the product's evidence base.

Quarterly growth meets a valuation test

In the first quarter of fiscal 2027, Medtronic generated USD 9.76 billion in revenue, up 13.70 percent from the prior-year quarter, according to MarketBeat. The same report said quarterly revenue exceeded the USD 9.55 billion analyst expectation, while the company set second-quarter fiscal 2027 adjusted earnings-per-share guidance at USD 1.32 to USD 1.34.

Medtronic's market capitalization was USD 110.6 billion as of October 2, 2026. Its NYSE 52-week range was USD 73.31 to USD 106.33, placing the latest primary-market quote of USD 86.38 below the yearly high while leaving the stock above its yearly low.

Euro quote stays below prior close

The Lang & Schwarz quote stood at EUR 76.90 on October 5, 2026 at 10:03 a.m. CEST, a 0.44 percent change versus the EUR 77.24 prior close dated October 2, 2026. The contrast is clear: current operating revenue is higher year over year, while the German euro quote remains below its previous session base.

The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.